MYC drives overexpression of telomerase RNA (hTR/TERC) in prostate cancer

Javier A. Baena-Del Valle, Qizhi Zheng, David M. Esopi, Michael Rubenstein, Gretchen K. Hubbard, Maria C. Moncaliano, Andrew Hruszkewycz, Ajay Vaghasia, S Yegnasubramanian, Sarah Wheelan, Alan Keith Meeker, Christopher M Heaphy, Mindy K. Graham, Angelo Michael Demarzo

Research output: Contribution to journalArticle

Abstract

Telomerase consists of at least two essential elements, an RNA component hTR or TERC that contains the template for telomere DNA addition and a catalytic reverse transcriptase (TERT). While expression of TERT has been considered the key rate-limiting component for telomerase activity, increasing evidence suggests an important role for the regulation of TERC in telomere maintenance and perhaps other functions in human cancer. By using three orthogonal methods including RNAseq, RT-qPCR, and an analytically validated chromogenic RNA in situ hybridization assay, we report consistent overexpression of TERC in prostate cancer. This overexpression occurs at the precursor stage (e.g. high-grade prostatic intraepithelial neoplasia or PIN) and persists throughout all stages of disease progression. Levels of TERC correlate with levels of MYC (a known driver of prostate cancer) in clinical samples and we also show the following: forced reductions of MYC result in decreased TERC levels in eight cancer cell lines (prostate, lung, breast, and colorectal); forced overexpression of MYC in PCa cell lines, and in the mouse prostate, results in increased TERC levels; human TERC promoter activity is decreased after MYC silencing; and MYC occupies the TERC locus as assessed by chromatin immunoprecipitation (ChIP). Finally, we show that knockdown of TERC by siRNA results in reduced proliferation of prostate cancer cell lines. These studies indicate that TERC is consistently overexpressed in all stages of prostatic adenocarcinoma and that its expression is regulated by MYC. These findings nominate TERC as a novel prostate cancer biomarker and therapeutic target.

Original languageEnglish (US)
Pages (from-to)11-24
Number of pages14
JournalJournal of Pathology
Volume244
Issue number1
DOIs
StatePublished - Jan 1 2018

Fingerprint

Prostatic Neoplasms
Telomerase
Telomere
Cell Line
telomerase RNA
Prostate
Prostatic Intraepithelial Neoplasia
Chromatin Immunoprecipitation
RNA-Directed DNA Polymerase
Tumor Biomarkers
Small Interfering RNA
In Situ Hybridization
Disease Progression
Neoplasms
Adenocarcinoma
Breast
Maintenance
RNA
Lung
DNA

Keywords

  • MYC
  • prostate carcinoma
  • RNA in situ hybridization
  • telomerase
  • TERC telomerase RNA component

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Baena-Del Valle, J. A., Zheng, Q., Esopi, D. M., Rubenstein, M., Hubbard, G. K., Moncaliano, M. C., ... Demarzo, A. M. (2018). MYC drives overexpression of telomerase RNA (hTR/TERC) in prostate cancer. Journal of Pathology, 244(1), 11-24. https://doi.org/10.1002/path.4980

MYC drives overexpression of telomerase RNA (hTR/TERC) in prostate cancer. / Baena-Del Valle, Javier A.; Zheng, Qizhi; Esopi, David M.; Rubenstein, Michael; Hubbard, Gretchen K.; Moncaliano, Maria C.; Hruszkewycz, Andrew; Vaghasia, Ajay; Yegnasubramanian, S; Wheelan, Sarah; Meeker, Alan Keith; Heaphy, Christopher M; Graham, Mindy K.; Demarzo, Angelo Michael.

In: Journal of Pathology, Vol. 244, No. 1, 01.01.2018, p. 11-24.

Research output: Contribution to journalArticle

Baena-Del Valle, JA, Zheng, Q, Esopi, DM, Rubenstein, M, Hubbard, GK, Moncaliano, MC, Hruszkewycz, A, Vaghasia, A, Yegnasubramanian, S, Wheelan, S, Meeker, AK, Heaphy, CM, Graham, MK & Demarzo, AM 2018, 'MYC drives overexpression of telomerase RNA (hTR/TERC) in prostate cancer', Journal of Pathology, vol. 244, no. 1, pp. 11-24. https://doi.org/10.1002/path.4980
Baena-Del Valle JA, Zheng Q, Esopi DM, Rubenstein M, Hubbard GK, Moncaliano MC et al. MYC drives overexpression of telomerase RNA (hTR/TERC) in prostate cancer. Journal of Pathology. 2018 Jan 1;244(1):11-24. https://doi.org/10.1002/path.4980
Baena-Del Valle, Javier A. ; Zheng, Qizhi ; Esopi, David M. ; Rubenstein, Michael ; Hubbard, Gretchen K. ; Moncaliano, Maria C. ; Hruszkewycz, Andrew ; Vaghasia, Ajay ; Yegnasubramanian, S ; Wheelan, Sarah ; Meeker, Alan Keith ; Heaphy, Christopher M ; Graham, Mindy K. ; Demarzo, Angelo Michael. / MYC drives overexpression of telomerase RNA (hTR/TERC) in prostate cancer. In: Journal of Pathology. 2018 ; Vol. 244, No. 1. pp. 11-24.
@article{9c3d68c4aeac479ca5e5cf09fcc65f04,
title = "MYC drives overexpression of telomerase RNA (hTR/TERC) in prostate cancer",
abstract = "Telomerase consists of at least two essential elements, an RNA component hTR or TERC that contains the template for telomere DNA addition and a catalytic reverse transcriptase (TERT). While expression of TERT has been considered the key rate-limiting component for telomerase activity, increasing evidence suggests an important role for the regulation of TERC in telomere maintenance and perhaps other functions in human cancer. By using three orthogonal methods including RNAseq, RT-qPCR, and an analytically validated chromogenic RNA in situ hybridization assay, we report consistent overexpression of TERC in prostate cancer. This overexpression occurs at the precursor stage (e.g. high-grade prostatic intraepithelial neoplasia or PIN) and persists throughout all stages of disease progression. Levels of TERC correlate with levels of MYC (a known driver of prostate cancer) in clinical samples and we also show the following: forced reductions of MYC result in decreased TERC levels in eight cancer cell lines (prostate, lung, breast, and colorectal); forced overexpression of MYC in PCa cell lines, and in the mouse prostate, results in increased TERC levels; human TERC promoter activity is decreased after MYC silencing; and MYC occupies the TERC locus as assessed by chromatin immunoprecipitation (ChIP). Finally, we show that knockdown of TERC by siRNA results in reduced proliferation of prostate cancer cell lines. These studies indicate that TERC is consistently overexpressed in all stages of prostatic adenocarcinoma and that its expression is regulated by MYC. These findings nominate TERC as a novel prostate cancer biomarker and therapeutic target.",
keywords = "MYC, prostate carcinoma, RNA in situ hybridization, telomerase, TERC telomerase RNA component",
author = "{Baena-Del Valle}, {Javier A.} and Qizhi Zheng and Esopi, {David M.} and Michael Rubenstein and Hubbard, {Gretchen K.} and Moncaliano, {Maria C.} and Andrew Hruszkewycz and Ajay Vaghasia and S Yegnasubramanian and Sarah Wheelan and Meeker, {Alan Keith} and Heaphy, {Christopher M} and Graham, {Mindy K.} and Demarzo, {Angelo Michael}",
year = "2018",
month = "1",
day = "1",
doi = "10.1002/path.4980",
language = "English (US)",
volume = "244",
pages = "11--24",
journal = "Journal of Pathology",
issn = "0022-3417",
publisher = "John Wiley and Sons Ltd",
number = "1",

}

TY - JOUR

T1 - MYC drives overexpression of telomerase RNA (hTR/TERC) in prostate cancer

AU - Baena-Del Valle, Javier A.

AU - Zheng, Qizhi

AU - Esopi, David M.

AU - Rubenstein, Michael

AU - Hubbard, Gretchen K.

AU - Moncaliano, Maria C.

AU - Hruszkewycz, Andrew

AU - Vaghasia, Ajay

AU - Yegnasubramanian, S

AU - Wheelan, Sarah

AU - Meeker, Alan Keith

AU - Heaphy, Christopher M

AU - Graham, Mindy K.

AU - Demarzo, Angelo Michael

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Telomerase consists of at least two essential elements, an RNA component hTR or TERC that contains the template for telomere DNA addition and a catalytic reverse transcriptase (TERT). While expression of TERT has been considered the key rate-limiting component for telomerase activity, increasing evidence suggests an important role for the regulation of TERC in telomere maintenance and perhaps other functions in human cancer. By using three orthogonal methods including RNAseq, RT-qPCR, and an analytically validated chromogenic RNA in situ hybridization assay, we report consistent overexpression of TERC in prostate cancer. This overexpression occurs at the precursor stage (e.g. high-grade prostatic intraepithelial neoplasia or PIN) and persists throughout all stages of disease progression. Levels of TERC correlate with levels of MYC (a known driver of prostate cancer) in clinical samples and we also show the following: forced reductions of MYC result in decreased TERC levels in eight cancer cell lines (prostate, lung, breast, and colorectal); forced overexpression of MYC in PCa cell lines, and in the mouse prostate, results in increased TERC levels; human TERC promoter activity is decreased after MYC silencing; and MYC occupies the TERC locus as assessed by chromatin immunoprecipitation (ChIP). Finally, we show that knockdown of TERC by siRNA results in reduced proliferation of prostate cancer cell lines. These studies indicate that TERC is consistently overexpressed in all stages of prostatic adenocarcinoma and that its expression is regulated by MYC. These findings nominate TERC as a novel prostate cancer biomarker and therapeutic target.

AB - Telomerase consists of at least two essential elements, an RNA component hTR or TERC that contains the template for telomere DNA addition and a catalytic reverse transcriptase (TERT). While expression of TERT has been considered the key rate-limiting component for telomerase activity, increasing evidence suggests an important role for the regulation of TERC in telomere maintenance and perhaps other functions in human cancer. By using three orthogonal methods including RNAseq, RT-qPCR, and an analytically validated chromogenic RNA in situ hybridization assay, we report consistent overexpression of TERC in prostate cancer. This overexpression occurs at the precursor stage (e.g. high-grade prostatic intraepithelial neoplasia or PIN) and persists throughout all stages of disease progression. Levels of TERC correlate with levels of MYC (a known driver of prostate cancer) in clinical samples and we also show the following: forced reductions of MYC result in decreased TERC levels in eight cancer cell lines (prostate, lung, breast, and colorectal); forced overexpression of MYC in PCa cell lines, and in the mouse prostate, results in increased TERC levels; human TERC promoter activity is decreased after MYC silencing; and MYC occupies the TERC locus as assessed by chromatin immunoprecipitation (ChIP). Finally, we show that knockdown of TERC by siRNA results in reduced proliferation of prostate cancer cell lines. These studies indicate that TERC is consistently overexpressed in all stages of prostatic adenocarcinoma and that its expression is regulated by MYC. These findings nominate TERC as a novel prostate cancer biomarker and therapeutic target.

KW - MYC

KW - prostate carcinoma

KW - RNA in situ hybridization

KW - telomerase

KW - TERC telomerase RNA component

UR - http://www.scopus.com/inward/record.url?scp=85039553458&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85039553458&partnerID=8YFLogxK

U2 - 10.1002/path.4980

DO - 10.1002/path.4980

M3 - Article

C2 - 28888037

AN - SCOPUS:85039553458

VL - 244

SP - 11

EP - 24

JO - Journal of Pathology

JF - Journal of Pathology

SN - 0022-3417

IS - 1

ER -